Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Meanwhile, Lilly gets in on the next-gen KRAS action.
But will the FDA accept the surrogate endpoint used in ASC4First?
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
This weekend’s oncology conference will feature at least 30 different ADC projects.